Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/med.21292 http://scihub22266oqcxt.onion/10.1002/med.21292 23722879!7168461!23722879     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=23722879&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Med+Res+Rev 2014 ; 34 (5): 895-917 Nephropedia Template TP {{tp|p=23722879|t=2014. Molecular biology and inhibitors of hepatitis A virus |pdf=|usr=}}{{23722879}} gab.com Text Molecular biology and inhibitors of hepatitis A virus JO: Med Res Rev http://www.kidney.de/pget.php?&tw=1&pmid=23722879 #FOAvip Hepatitis A virus (HAV) is a faeco-orally transmitted picornavirus and is one of the main causes of acute hepatitis worldwide. An overview of the molecular biology of HAV is presented with an emphasis on recent findings. Immune evasion strategies and a possible correlation between HAV and atopy are discussed as well. Despite the availability of efficient vaccines, antiviral drugs targeting HAV are required to treat severe cases of fulminant hepatitis, contain outbreaks, and halt the potential spread of vaccine-escape variants. Additionally, such drugs could be used to shorten the period of illness and decrease associated economical costs. Several known inhibitors of HAV with various mechanisms of action will be discussed. Since none of these molecules is readily useable in the clinic and since the availability of an anti-HAV drug would be of clinical importance, increased efforts should be targeted toward discovery and development of such antivirals. Twit Text FOAVip Molecular biology and inhibitors of hepatitis A virus ????Med Res Rev http://www.kidney.de/pget.php?&tw=1&pmid=23722879 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=23722879 #FOAvip English Wikipedia <ref>{{Cite pmid|23722879}}</ref> Molecular biology and inhibitors of hepatitis A virus #MMPMID23722879 Debing Y; Neyts J; Thibaut HJ Med Res Rev 2014[Sep]; 34 (5): 895-917 PMID23722879show ga Hepatitis A virus (HAV) is a faeco-orally transmitted picornavirus and is one of the main causes of acute hepatitis worldwide. An overview of the molecular biology of HAV is presented with an emphasis on recent findings. Immune evasion strategies and a possible correlation between HAV and atopy are discussed as well. Despite the availability of efficient vaccines, antiviral drugs targeting HAV are required to treat severe cases of fulminant hepatitis, contain outbreaks, and halt the potential spread of vaccine-escape variants. Additionally, such drugs could be used to shorten the period of illness and decrease associated economical costs. Several known inhibitors of HAV with various mechanisms of action will be discussed. Since none of these molecules is readily useable in the clinic and since the availability of an anti-HAV drug would be of clinical importance, increased efforts should be targeted toward discovery and development of such antivirals. |Antiviral Agents/*pharmacology/therapeutic use[MESH] |Cells, Cultured[MESH] |Genome, Viral[MESH] |Hepatitis A virus/*drug effects/genetics/physiology[MESH] |Hepatitis A/drug therapy[MESH] |Humans[MESH] |Immune Evasion[MESH] |Protein Biosynthesis/drug effects[MESH] |T-Lymphocytes, Cytotoxic/immunology[MESH]Molecular biology and inhibitors of hepatitis A virus (epmc).pdf DeepDyve Pubget Overpricing